Lifecore Biomedical reported an EPS of -$0.47, missing the estimated EPS by a significant margin.
The company’s revenue was $35.15 million, falling short of the estimated $37.94 million.
Lifecore Biomedical has a negative P/E ratio of approximately -4.87 and maintains a strong liquidity position with a current ratio of approximately 2.71.
Lifecore Biomedical, Inc. (NASDAQ:LFCR) operates in the medical, biomedical, and genetics industry, focusing on developing and manufacturing products for the healthcare sector. Despite its strategic initiatives, LFCR faces challenges in meeting financial expectations, as evidenced by its recent earnings report.
On April 3, 2025, LFCR reported an earnings per share (EPS) of -$0.47, which was below the estimated EPS of -$0.14. This represents a significant negative earnings surprise of 35.71%, as highlighted by Zacks. The company’s actual revenue for this period was $35.15 million, falling short of the estimated $37.94 million by 3.95%.
Despite the challenges, Lifecore has made strategic moves to strengthen its position. The company signed multiple development agreements with new and existing customers, indicating a strategic expansion of its business relationships. Additionally, Lifecore raised approximately $17 million through the sale of excess capital equipment, bolstering its balance sheet.
Financially, LFCR has a negative price-to-earnings (P/E) ratio of approximately -4.87, indicating current losses. The price-to-sales ratio stands at about 1.93, suggesting investors are willing to pay $1.93 for every dollar of sales. The company maintains a strong liquidity position with a current ratio of approximately 2.71, indicating its ability to cover short-term liabilities.
